Sumitomo Pharma’s FY2026 individual performance was \u00a5249,530 million in sales, \u00a519,359 million in operating income, \u00a562,940 million in ordinary income, and \u00a5114,981 million in net income, all significantly increased compared to the previous period. The differences are due to asset transfer and dividend recognition.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4005","jir_company_name":"Sumitomo Chemical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4005-20260513-03.pdf","jir_short_summary":"Sumitomo Pharma's FY2026 individual performance was \u00a5249,530 million in sales, \u00a519,359 million in operating income, \u00a562,940 million in ordinary income, and \u00a5114,981 million in net income, all significantly increased compared to the previous period. The differences are due to asset transfer and dividend recognition.","jir_summary":"### Performance Overview\nSumitomo Pharma's FY2026 individual performance recorded sales of \u00a5249,530 million, operating income of \u00a519,359 million, ordinary income of \u00a562,940 million, and net income of \u00a5114,981 million, all substantially increased from the previous period. The revenue growth was mainly due to sales recognition from the transfer of US core product patents and dividend income, with notable increases in both sales and ordinary income.\n\n### Background of Discrepancies and Future Impact\nThe main reasons for the differences are the recognition of sales through asset transfer by Sumitomo Pharma and the reflection of dividends received from SMPS Corporation. As a result, net income also exceeded the previous period. However, the impact on Sumitomo Chemical's consolidated performance is expected to be minimal, and no major changes are anticipated in future business strategies or performance forecasts.","jir_financial_highlights":"Sales Revenue: \u00a5249,530 million (up 82.9% YoY)\nOperating Income: \u00a519,359 million (up 66.8% YoY)\nOrdinary Income: \u00a562,940 million (up 423.3% YoY)\nNet Income attributable to owners of parent: \u00a5114,981 million (up 8.3% YoY)","jir_category":"","jir_hashtags":"#SumitomoChemicals, #FinancialResults, #JapaneseStocks","jir_key_figures":"Sales Revenue: \u00a5249,530 million (up 82.9% YoY)\nOperating Income: \u00a519,359 million (up 66.8% YoY)\nOrdinary Income: \u00a562,940 million (up 423.3% YoY)","jir_meta_title":"\u3010Sumitomo Chemical\u3011Sumitomo Pharma Performance Discrepancies and Outlook for the Current Period | May 2026","jir_meta_description":"Explanation of Sumitomo Chemical's consolidated subsidiary Sumitomo Pharma's FY2026 performance discrepancies and background. Sales of \u00a5249.53 billion and net income of \u00a5114.98 billion saw significant increases.","jir_og_title":"Sumitomo Chemical | Discrepancies and Outlook of Sumitomo Pharma's Performance | May 2026","jir_og_description":"Detailed explanation of Sumitomo Chemical's subsidiary Sumitomo Pharma's FY2026 performance discrepancies and background. Sales reached \u00a5249.5 billion, with net income exceeding \u00a5115 billion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7702,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48804","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n